Intelligence / Healthtech / New Clinical Trials
ClinicalLIVEUpdated 18 Nov 2026
New Clinical Trials
Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.
Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.
Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777 Growth
By month
777
Signals
What the register says this week, and why it matters if you sell into it.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
- 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
- A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
PostedSponsorStudyPhaseStatus
16 Nov 2026Biosensors Europe SAUnited KingdomStudy of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE)Early Phase 1Not Yet Recruiting12 Nov 2026MSK Doctors & Associates LtdUnited KingdomElectrical Muscle Stimulation (EMS) Versus Standard Physiotherapy for Quadriceps Recovery Following Total Knee ReplacementNot applicableRecruiting12 Nov 2026Novo Nordisk A/SUnited States, Argentina, BrazilA Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothPhase 3Not Yet Recruiting12 Nov 2026Novo Nordisk A/SUnited States, Argentina, AustraliaAMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothPhase 3Not Yet Recruiting10 Nov 2026Eli Lilly and CompanyUnited States, Bulgaria, HungaryA Study of Brenipatide in Participants With Major Depressive DisorderPhase 2Not Yet Recruiting10 Nov 2026Eli Lilly and CompanyUnited States, France, JapanA Study of LY4336619 in Adult Participants With Advanced Solid TumorsPhase 1Not Yet Recruiting9 Nov 2026Boehringer IngelheimUnited States, Belgium, FinlandA Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard TreatmentPhase 2Not Yet Recruiting9 Nov 2026Richmond Research InstituteUnited KingdomChronic Respiratory Disease Participant Engagement StudyRecruiting5 Nov 2026ModernaTX, Inc.United KingdomA Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy Adult ParticipantsPhase 1Not Yet Recruiting5 Nov 2026Novo Nordisk A/SUnited States, Argentina, AustraliaA Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityPhase 3Not Yet Recruiting4 Nov 2026Boehringer IngelheimUnited States, Argentina, AustriaA Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Phase 3Not Yet Recruiting4 Nov 2026GlaxoSmithKlineUnited States, United KingdomA Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Phase 2Recruiting2 Nov 2026AstraZenecaUnited KingdomA Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234Phase 1Not Yet Recruiting29 Oct 2026Aymes International LimitedUnited KingdomTolerance and Acceptability of an Oral Nutrition SupplementNot applicableNot Yet Recruiting28 Oct 2026Odyssey Therapeutics, Inc.United KingdomThe Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male ParticipantsPhase 1Recruiting27 Oct 2026Pneumagen Ltd, a subsidiary of NorthLinks BioUnited KingdomNasal Residency of HEX17Phase 1Not Yet Recruiting27 Oct 2026Swedish Orphan BiovitrumBrazil, Canada, FinlandA Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant RecipientsPhase 3Recruiting26 Oct 2026AeroRx Therapeutics Inc.United KingdomPhase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD PatientsPhase 2Recruiting21 Oct 2026Probi ABUnited KingdomEffects of Probiotics on Skin Health in Healthy WomenNot applicableNot Yet Recruiting20 Oct 2026Hoffmann-La RocheDenmark, United KingdomA Study of RO7821657 in Participants With Solid TumorsPhase 1Recruiting20 Oct 2026Mitra BioBelgium, Germany, SpainDevelopment and Multi-Centre Validation of a Novel Non-Invasive Melanoma Molecular Diagnostic TestRecruiting// How AOS uses this